

General Commissioning Policy

Treatment	Keratoacanthoma
For the treatment of	Keratoacanthoma
Background	From April 2013, NHS England took over responsibility for commissioning activity in primary care, where initial conservative treatment takes place. NHS Scarborough and Ryedale CCG is responsible for commissioning activity in secondary care, and this policy sets out the referral criteria for the referral to secondary care for the management of Keratoacanthoma.
Definition	<p>Keratoacanthoma is a rapidly evolving skin lesion that resembles squamous cell carcinoma both clinically and histologically.</p> <p>Images</p> <p>It usually occurs in sun-damaged skin and typically grows rapidly over 4-6 weeks to produce a dome shaped nodule with central ulceration or a keratin plug looking like a small volcano.</p> <p>Following this the lesion spontaneously resolves over 4-6 months</p> <p>Exclude Red Flag Symptoms Difficult to distinguish clinically from squamous cell carcinomas</p>
Management	All need referral for excision to either Dermatology or Maxillofacial surgeons under the 2 week rule as cannot exclude an SCC clinically
Investigations prior to referral	None
Information to include in referral letter	<ul style="list-style-type: none"> • Site and size of lesion • History and duration of complaint • Outline treatments already advised and tried including effects • Number of consultations patient has had for this condition in the last 6 months • Photograph is desirable • Relevant past medical /surgical history including any family history of cancer • Current regular medication • BMI/smoking status
Patient Leaflets	<p>Patient Information leaflet about Keratoacanthoma from the British Association of Dermatologists – click here</p> <p>Excellent website with very good images – click here</p>
Effective from	November 2014
Reviewed	April 2017
Review Date	2019

Responsible GP – Dr Peter Billingsley, SRCCG	Approved: April 2017
Responsible Consultant – Ms Kathryn Thomson, YTHFT	Date published: April 2017
Responsible Pharmacist – Ms Rachel Ainger, SRCCG Medicines Mngt	NHS Scarborough & Ryedale Clinical Commissioning Group

Contact for this policy	Service Improvement Team scrccg.rssifr@nhs.net
-------------------------	--

References:

1. <http://www.pcds.org.uk/clinical-guidance/keratoacanthoma>

Responsible GP – Dr Peter Billingsley, SRCCG	Approved: April 2017
Responsible Consultant – Ms Kathryn Thomson, YTHFT	Date published: April 2017
Responsible Pharmacist – Ms Rachel Ainger, SRCCG Medicines Mngt	NHS Scarborough & Ryedale Clinical Commissioning Group